Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole.

Vasicek EM, Berkow EL, Bruno VM, Mitchell AP, Wiederhold NP, Barker KS, Rogers PD.

Antimicrob Agents Chemother. 2014 Nov;58(11):6807-18. doi: 10.1128/AAC.00064-14.

2.

UPC2 is universally essential for azole antifungal resistance in Candida albicans.

Vasicek EM, Berkow EL, Flowers SA, Barker KS, Rogers PD.

Eukaryot Cell. 2014 Jul;13(7):933-46. doi: 10.1128/EC.00221-13.

3.

UPC2A is required for high-level azole antifungal resistance in Candida glabrata.

Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD.

Antimicrob Agents Chemother. 2014 Aug;58(8):4543-54. doi: 10.1128/AAC.02217-13.

4.
5.

Mutations in transcription factor Mrr2p contribute to fluconazole resistance in clinical isolates of Candida albicans.

Wang Y, Liu JY, Shi C, Li WJ, Zhao Y, Yan L, Xiang MJ.

Int J Antimicrob Agents. 2015 Nov;46(5):552-9. doi: 10.1016/j.ijantimicag.2015.08.001.

PMID:
26404130
6.

Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans.

Morio F, Pagniez F, Besse M, Gay-andrieu F, Miegeville M, Le Pape P.

Int J Antimicrob Agents. 2013 Nov;42(5):410-5. doi: 10.1016/j.ijantimicag.2013.07.013.

PMID:
24051054
7.

An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans.

Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2010 Jan;54(1):353-9. doi: 10.1128/AAC.01102-09.

8.

Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.

Sanglard D, Coste AT.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):229-38. doi: 10.1128/AAC.02157-15.

10.

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF.

Antimicrob Agents Chemother. 2001 Oct;45(10):2676-84.

11.

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J.

Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86.

12.

Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans.

Barker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, Eckstein J, Barbuch R, Bard M, Rogers PD.

J Antimicrob Chemother. 2004 Aug;54(2):376-85.

PMID:
15201233
13.

Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India.

Mane A, Vidhate P, Kusro C, Waman V, Saxena V, Kulkarni-Kale U, Risbud A.

Mycoses. 2016 Feb;59(2):93-100. doi: 10.1111/myc.12439.

PMID:
26648048
14.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
15.

Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.

Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhäuser J, Rogers PD.

Eukaryot Cell. 2012 Oct;11(10):1289-99. doi: 10.1128/EC.00215-12.

16.

Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D.

Antimicrob Agents Chemother. 2010 Apr;54(4):1476-83. doi: 10.1128/AAC.01645-09.

17.

Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.

Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhäuser J.

Antimicrob Agents Chemother. 1998 Dec;42(12):3065-72.

18.
20.

In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans.

Guo N, Ling G, Liang X, Jin J, Fan J, Qiu J, Song Y, Huang N, Wu X, Wang X, Deng X, Deng X, Yu L.

Mycoses. 2011 Sep;54(5):e400-6. doi: 10.1111/j.1439-0507.2010.01935.x.

PMID:
21910756
Items per page

Supplemental Content

Support Center